Oncology Based In-Vivo CRO Market Report by Indication (Blood Cancer, Solid Tumors, and Others), Model (Syngeneic, Xenograft, Patient Derived Xenograft (PDX), and Others), Application (Hospitals, Rehabilitation Centers), and Region 2024-2032
The global oncology based in-vivo CRO market size reached US$ 1.2 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 2.3 Billion by 2032, exhibiting a growth rate (CAGR) of 6.9% during 2024-2032.
Oncology refers to a branch of medicine that studies, diagnoses, and treats cancer using biopsy, endoscopy, X-ray, computed tomography (CT) scanning, magnetic resonance imaging (MRI), positron emission tomography (PET) scanning, and ultrasound. It offers hormonal therapy, immunotherapy, radiotherapy, and oral therapies to patients for tolerating and easing the side effects of cancer. At present, there is a rise in the demand for oncology based in-vivo CRO across the globe due to the development of several investigational compounds by contract research organizations (CROs) for treating cancer.
Oncology Based In-Vivo CRO Market Trends:
The growing prevalence of cancer around the world represents one of the key factors driving the market. Moreover, governments of several countries across the globe are extensively investing in research and development (R&D) activities. This, along with the rising expertise in cancer treatment by contract research organizations (CROs), is propelling the growth of the market. In addition, there is an increase in the innovation of genetic engineering for manipulating deoxyribonucleic acid (DNA) and altering the characteristics of organisms. This, coupled with the growing focus on oncogene study to regulate proliferation, growth, and differentiation of cells, is positively influencing the market. Besides this, the wide availability of medicines, along with the expanding healthcare industry, is catalyzing the demand for oncology based in-vivo CRO worldwide. Apart from this, the cost-efficiency offered by contract research organizations (CROs) compared to an in-house study is offering lucrative growth opportunities to industry investors. Additionally, there is an increase in the adoption of telehealth and virtual clinical trials in the healthcare industry for ensuring the safety of cancer patients. This is projected to bolster the growth of the market.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global oncology based in-vivo CRO market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on indication, model and application.
Breakup by Indication:
Blood Cancer
Solid Tumors
Others
Breakup by Model:
Syngeneic
Xenograft
Patient Derived Xenograft (PDX)
Others
Breakup by Application:
Hospitals
Rehabilitation Centers
Breakup by Region:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Champions Oncology Inc., Charles River Laboratories International Inc., Crown Bioscience Inc., Eurofins Scientific, Evotec SE, ICON Plc, Labcorp Drug Development (Laboratory Corporation of America Holdings), Living Tumor Laboratory, Taconic Biosciences Inc., The Jackson Laboratory, WuXi AppTec and Xentech.
Key Questions Answered in This Report
1. What was the size of the global oncology based in-vivo CRO market in 2023?
2. What is the expected growth rate of the global oncology based in-vivo CRO market during 2024-2032?
3. What are the key factors driving the global oncology based in-vivo CRO market?
4. What has been the impact of COVID-19 on the global oncology based in-vivo CRO market?
5. What is the breakup of the global oncology based in-vivo CRO market based on the indication?
6. What is the breakup of the global oncology based in-vivo CRO market based on the model?
7. What are the key regions in the global oncology based in-vivo CRO market?
8. Who are the key players/companies in the global oncology based in-vivo CRO market?
Oncology refers to a branch of medicine that studies, diagnoses, and treats cancer using biopsy, endoscopy, X-ray, computed tomography (CT) scanning, magnetic resonance imaging (MRI), positron emission tomography (PET) scanning, and ultrasound. It offers hormonal therapy, immunotherapy, radiotherapy, and oral therapies to patients for tolerating and easing the side effects of cancer. At present, there is a rise in the demand for oncology based in-vivo CRO across the globe due to the development of several investigational compounds by contract research organizations (CROs) for treating cancer.
Oncology Based In-Vivo CRO Market Trends:
The growing prevalence of cancer around the world represents one of the key factors driving the market. Moreover, governments of several countries across the globe are extensively investing in research and development (R&D) activities. This, along with the rising expertise in cancer treatment by contract research organizations (CROs), is propelling the growth of the market. In addition, there is an increase in the innovation of genetic engineering for manipulating deoxyribonucleic acid (DNA) and altering the characteristics of organisms. This, coupled with the growing focus on oncogene study to regulate proliferation, growth, and differentiation of cells, is positively influencing the market. Besides this, the wide availability of medicines, along with the expanding healthcare industry, is catalyzing the demand for oncology based in-vivo CRO worldwide. Apart from this, the cost-efficiency offered by contract research organizations (CROs) compared to an in-house study is offering lucrative growth opportunities to industry investors. Additionally, there is an increase in the adoption of telehealth and virtual clinical trials in the healthcare industry for ensuring the safety of cancer patients. This is projected to bolster the growth of the market.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global oncology based in-vivo CRO market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on indication, model and application.
Breakup by Indication:
Blood Cancer
Solid Tumors
Others
Breakup by Model:
Syngeneic
Xenograft
Patient Derived Xenograft (PDX)
Others
Breakup by Application:
Hospitals
Rehabilitation Centers
Breakup by Region:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Champions Oncology Inc., Charles River Laboratories International Inc., Crown Bioscience Inc., Eurofins Scientific, Evotec SE, ICON Plc, Labcorp Drug Development (Laboratory Corporation of America Holdings), Living Tumor Laboratory, Taconic Biosciences Inc., The Jackson Laboratory, WuXi AppTec and Xentech.
Key Questions Answered in This Report
1. What was the size of the global oncology based in-vivo CRO market in 2023?
2. What is the expected growth rate of the global oncology based in-vivo CRO market during 2024-2032?
3. What are the key factors driving the global oncology based in-vivo CRO market?
4. What has been the impact of COVID-19 on the global oncology based in-vivo CRO market?
5. What is the breakup of the global oncology based in-vivo CRO market based on the indication?
6. What is the breakup of the global oncology based in-vivo CRO market based on the model?
7. What are the key regions in the global oncology based in-vivo CRO market?
8. Who are the key players/companies in the global oncology based in-vivo CRO market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 INTRODUCTION
4.1 Overview
4.2 Key Industry Trends
5 GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 MARKET BREAKUP BY INDICATION
6.1 Blood Cancer
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Solid Tumors
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Others
6.3.1 Market Trends
6.3.2 Market Forecast
7 MARKET BREAKUP BY MODEL
7.1 Syngeneic
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Xenograft
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Patient Derived Xenograft (PDX)
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 Others
7.4.1 Market Trends
7.4.2 Market Forecast
8 MARKET BREAKUP BY APPLICATION
8.1 Hospitals
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Rehabilitation Centers
8.2.1 Market Trends
8.2.2 Market Forecast
9 MARKET BREAKUP BY REGION
9.1 North America
9.1.1 United States
9.1.1.1 Market Trends
9.1.1.2 Market Forecast
9.1.2 Canada
9.1.2.1 Market Trends
9.1.2.2 Market Forecast
9.2 Asia-Pacific
9.2.1 China
9.2.1.1 Market Trends
9.2.1.2 Market Forecast
9.2.2 Japan
9.2.2.1 Market Trends
9.2.2.2 Market Forecast
9.2.3 India
9.2.3.1 Market Trends
9.2.3.2 Market Forecast
9.2.4 South Korea
9.2.4.1 Market Trends
9.2.4.2 Market Forecast
9.2.5 Australia
9.2.5.1 Market Trends
9.2.5.2 Market Forecast
9.2.6 Indonesia
9.2.6.1 Market Trends
9.2.6.2 Market Forecast
9.2.7 Others
9.2.7.1 Market Trends
9.2.7.2 Market Forecast
9.3 Europe
9.3.1 Germany
9.3.1.1 Market Trends
9.3.1.2 Market Forecast
9.3.2 France
9.3.2.1 Market Trends
9.3.2.2 Market Forecast
9.3.3 United Kingdom
9.3.3.1 Market Trends
9.3.3.2 Market Forecast
9.3.4 Italy
9.3.4.1 Market Trends
9.3.4.2 Market Forecast
9.3.5 Spain
9.3.5.1 Market Trends
9.3.5.2 Market Forecast
9.3.6 Russia
9.3.6.1 Market Trends
9.3.6.2 Market Forecast
9.3.7 Others
9.3.7.1 Market Trends
9.3.7.2 Market Forecast
9.4 Latin America
9.4.1 Brazil
9.4.1.1 Market Trends
9.4.1.2 Market Forecast
9.4.2 Mexico
9.4.2.1 Market Trends
9.4.2.2 Market Forecast
9.4.3 Others
9.4.3.1 Market Trends
9.4.3.2 Market Forecast
9.5 Middle East and Africa
9.5.1 Market Trends
9.5.2 Market Breakup by Country
9.5.3 Market Forecast
10 SWOT ANALYSIS
10.1 Overview
10.2 Strengths
10.3 Weaknesses
10.4 Opportunities
10.5 Threats
11 VALUE CHAIN ANALYSIS
12 PORTERS FIVE FORCES ANALYSIS
12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes
13 PRICE ANALYSIS
14 COMPETITIVE LANDSCAPE
14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
14.3.1 Champions Oncology Inc.
14.3.1.1 Company Overview
14.3.1.2 Product Portfolio
14.3.1.3 Financials
14.3.2 Charles River Laboratories International Inc.
14.3.2.1 Company Overview
14.3.2.2 Product Portfolio
14.3.2.3 Financials
14.3.2.4 SWOT Analysis
14.3.3 Crown Bioscience Inc.
14.3.3.1 Company Overview
14.3.3.2 Product Portfolio
14.3.4 Eurofins Scientific
14.3.4.1 Company Overview
14.3.4.2 Product Portfolio
14.3.4.3 Financials
14.3.4.4 SWOT Analysis
14.3.5 Evotec SE
14.3.5.1 Company Overview
14.3.5.2 Product Portfolio
14.3.5.3 Financials
14.3.5.4 SWOT Analysis
14.3.6 ICON Plc
14.3.6.1 Company Overview
14.3.6.2 Product Portfolio
14.3.6.3 Financials
14.3.6.4 SWOT Analysis
14.3.7 Labcorp Drug Development (Laboratory Corporation of America Holdings)
14.3.7.1 Company Overview
14.3.7.2 Product Portfolio
14.3.7.3 SWOT Analysis
14.3.8 Living Tumor Laboratory
14.3.8.1 Company Overview
14.3.8.2 Product Portfolio
14.3.9 Taconic Biosciences Inc.
14.3.9.1 Company Overview
14.3.9.2 Product Portfolio
14.3.10 The Jackson Laboratory
14.3.10.1 Company Overview
14.3.10.2 Product Portfolio
14.3.11 WuXi AppTec
14.3.11.1 Company Overview
14.3.11.2 Product Portfolio
14.3.11.3 Financials
14.3.12 Xentech
14.3.12.1 Company Overview
14.3.12.2 Product Portfolio
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 INTRODUCTION
4.1 Overview
4.2 Key Industry Trends
5 GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 MARKET BREAKUP BY INDICATION
6.1 Blood Cancer
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Solid Tumors
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Others
6.3.1 Market Trends
6.3.2 Market Forecast
7 MARKET BREAKUP BY MODEL
7.1 Syngeneic
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Xenograft
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Patient Derived Xenograft (PDX)
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 Others
7.4.1 Market Trends
7.4.2 Market Forecast
8 MARKET BREAKUP BY APPLICATION
8.1 Hospitals
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Rehabilitation Centers
8.2.1 Market Trends
8.2.2 Market Forecast
9 MARKET BREAKUP BY REGION
9.1 North America
9.1.1 United States
9.1.1.1 Market Trends
9.1.1.2 Market Forecast
9.1.2 Canada
9.1.2.1 Market Trends
9.1.2.2 Market Forecast
9.2 Asia-Pacific
9.2.1 China
9.2.1.1 Market Trends
9.2.1.2 Market Forecast
9.2.2 Japan
9.2.2.1 Market Trends
9.2.2.2 Market Forecast
9.2.3 India
9.2.3.1 Market Trends
9.2.3.2 Market Forecast
9.2.4 South Korea
9.2.4.1 Market Trends
9.2.4.2 Market Forecast
9.2.5 Australia
9.2.5.1 Market Trends
9.2.5.2 Market Forecast
9.2.6 Indonesia
9.2.6.1 Market Trends
9.2.6.2 Market Forecast
9.2.7 Others
9.2.7.1 Market Trends
9.2.7.2 Market Forecast
9.3 Europe
9.3.1 Germany
9.3.1.1 Market Trends
9.3.1.2 Market Forecast
9.3.2 France
9.3.2.1 Market Trends
9.3.2.2 Market Forecast
9.3.3 United Kingdom
9.3.3.1 Market Trends
9.3.3.2 Market Forecast
9.3.4 Italy
9.3.4.1 Market Trends
9.3.4.2 Market Forecast
9.3.5 Spain
9.3.5.1 Market Trends
9.3.5.2 Market Forecast
9.3.6 Russia
9.3.6.1 Market Trends
9.3.6.2 Market Forecast
9.3.7 Others
9.3.7.1 Market Trends
9.3.7.2 Market Forecast
9.4 Latin America
9.4.1 Brazil
9.4.1.1 Market Trends
9.4.1.2 Market Forecast
9.4.2 Mexico
9.4.2.1 Market Trends
9.4.2.2 Market Forecast
9.4.3 Others
9.4.3.1 Market Trends
9.4.3.2 Market Forecast
9.5 Middle East and Africa
9.5.1 Market Trends
9.5.2 Market Breakup by Country
9.5.3 Market Forecast
10 SWOT ANALYSIS
10.1 Overview
10.2 Strengths
10.3 Weaknesses
10.4 Opportunities
10.5 Threats
11 VALUE CHAIN ANALYSIS
12 PORTERS FIVE FORCES ANALYSIS
12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes
13 PRICE ANALYSIS
14 COMPETITIVE LANDSCAPE
14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
14.3.1 Champions Oncology Inc.
14.3.1.1 Company Overview
14.3.1.2 Product Portfolio
14.3.1.3 Financials
14.3.2 Charles River Laboratories International Inc.
14.3.2.1 Company Overview
14.3.2.2 Product Portfolio
14.3.2.3 Financials
14.3.2.4 SWOT Analysis
14.3.3 Crown Bioscience Inc.
14.3.3.1 Company Overview
14.3.3.2 Product Portfolio
14.3.4 Eurofins Scientific
14.3.4.1 Company Overview
14.3.4.2 Product Portfolio
14.3.4.3 Financials
14.3.4.4 SWOT Analysis
14.3.5 Evotec SE
14.3.5.1 Company Overview
14.3.5.2 Product Portfolio
14.3.5.3 Financials
14.3.5.4 SWOT Analysis
14.3.6 ICON Plc
14.3.6.1 Company Overview
14.3.6.2 Product Portfolio
14.3.6.3 Financials
14.3.6.4 SWOT Analysis
14.3.7 Labcorp Drug Development (Laboratory Corporation of America Holdings)
14.3.7.1 Company Overview
14.3.7.2 Product Portfolio
14.3.7.3 SWOT Analysis
14.3.8 Living Tumor Laboratory
14.3.8.1 Company Overview
14.3.8.2 Product Portfolio
14.3.9 Taconic Biosciences Inc.
14.3.9.1 Company Overview
14.3.9.2 Product Portfolio
14.3.10 The Jackson Laboratory
14.3.10.1 Company Overview
14.3.10.2 Product Portfolio
14.3.11 WuXi AppTec
14.3.11.1 Company Overview
14.3.11.2 Product Portfolio
14.3.11.3 Financials
14.3.12 Xentech
14.3.12.1 Company Overview
14.3.12.2 Product Portfolio
